Timing and Patterns of Relapse-Related Events Following Adjuvant CDK4/6 Inhibitors Combined With Endocrine Therapy in Patients With HR-Positive, HER2-Negative Early Breast Cancer.

Kisqali (ribociclib) - Novartis

Ibrance (palbociclib) - Pfizer

Verzenio (abemaciclib) - Eli Lilly

http://www.ncbi.nlm.nih.gov/pubmed/42634184

Huihui Chen; Shijie Wu; Wei Lu; Xianan Guo; Yangyang Shan; Yiding Chen; Yunxiang Zhou

Aug 25, 2026